Last reviewed · How we verify
Huperzine A Injection
Huperzine A inhibits acetylcholinesterase, increasing acetylcholine levels in the brain to improve cognitive function.
Huperzine A inhibits acetylcholinesterase, increasing acetylcholine levels in the brain to improve cognitive function. Used for Alzheimer's disease, Age-related cognitive decline, Myasthenia gravis.
At a glance
| Generic name | Huperzine A Injection |
|---|---|
| Sponsor | Second Affiliated Hospital of Wenzhou Medical University |
| Drug class | Acetylcholinesterase inhibitor |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Huperzine A is a reversible inhibitor of the enzyme acetylcholinesterase, which normally breaks down the neurotransmitter acetylcholine. By blocking this enzyme, the drug increases acetylcholine concentration in the central nervous system, enhancing cholinergic neurotransmission. This mechanism is thought to improve memory, cognition, and neuronal protection in neurodegenerative conditions.
Approved indications
- Alzheimer's disease
- Age-related cognitive decline
- Myasthenia gravis
Common side effects
- Nausea
- Dizziness
- Headache
- Muscle cramps
- Bradycardia
Key clinical trials
- A Study of Huperzine A Injection in Reducing Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Surgery (NA)
- The Study of Pharmacokinetics and Pharmacodynamics of Huperzine a Injection in Healthy Chinese Subjects (PHASE1)
- The Study of Ginkgo Leaf Dropping Pills and Huperzine a Injection Combined with Median Nerve Electrical Stimulation in the Treatment of Cognitive Impairment After Brain Injury (PHASE4)
- The Effect of Huperzine A Injection on Postoperative Cognitive Dysfunction in Patients With Aneurysmal Subarachnoid Hemorrhage: a Pilot Study (PHASE4)
- Clinical Study of Huperzine A in the Treatment of Patients With Hypertensive Cerebral Hemorrhage (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Huperzine A Injection CI brief — competitive landscape report
- Huperzine A Injection updates RSS · CI watch RSS
- Second Affiliated Hospital of Wenzhou Medical University portfolio CI